Table 2:
Cox regression model results on thromboembolic (Model 1) and hemorrhagic events (Model 2).
| Model 1: | Model 2: | |||
|---|---|---|---|---|
| N of patients = 368 | N of patients = 368 | |||
| N of thromboembolic events = 30 | N of hemorrhagic events = 65 | |||
| HR (95%CI) | P-value | HR (95%CI) | P-value | |
| LAA occlusion vs warfarin | 0.19 (0.04–0.96) | 0.045 | 0.37 (0.16–0.83) | 0.017 |
| LAA occlusion vs No-OAT | 0.16 (0.04–0.66) | 0.011 | 0.51 (0.23–1.12) | 0.094 |
| Gender (males) | 0.98 (0.43–2.24) | 0.954 | 1.2 (0.68–2.15) | 0.529 |
| Age (yrs) | 1.01 (0.96–1.07) | 0.634 | 1.02 (0.98–1.05) | 0.283 |
| Dialytic age (yrs) | 0.95 (0.88–1.04) | 0.261 | 1.03 (0.99–1.06) | 0.111 |
| CHA2DS2VASc (for each point) | 1.22 (0.88–1.7) | 0.236 | 0.97 (0.74–1.27) | 0.822 |
| HASBLED (for each point) | 1.26 (0.71–2.25) | 0.436 | 1.17 (0.76–1.8) | 0.466 |
| Persistent vs paroxysmal AF | 0.62 (0.25–1.55) | 0.309 | 1.24 (0.6–2.56) | 0.567 |
| Permanent vs paroxysmal AF | 0.56 (0.2–1.58) | 0.270 | 1.33 (0.64–2.77) | 0.442 |
| Dyslipidemia | 1.15 (0.52–2.54) | 0.723 | 0.72 (0.4–1.28) | 0.260 |
| Peripheral artery disease | 0.61 (0.24–1.55) | 0.299 | 0.95 (0.52–1.72) | 0.863 |
| Previous major bleedings | 0.94 (0.33–2.65) | 0.901 | 1.77 (0.93–3.37) | 0.085 |
| Antiplatelet therapy | 1.11 (0.46–2.65) | 0.813 | 0.74 (0.4–1.36) | 0.334 |
AF, atrial fibrillation; LAA, left atrial appendage; OAT, oral anticoagulant therapy.